Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Astera Labs insider amendment reports multiple disposals and gifts of common stock by Michael Truett Tate, the companys CFO and trustee of the Tate Trust. The Form 4/A shows sales on 08/07/2025 and 08/08/2025: reported disposals include 43,184, 7,550, 15,141, and 34,125 shares sold at weighted-average prices ranging roughly from $169.05 to $174.04. The filing also records two bona fide gifts of 7,500 and 10,000 shares to non-affiliated recipients. Following the reported transactions the filing shows 501,496 shares beneficially owned indirectly by the Tate Trust. The amendment clarifies that a previously reported acquisition by GlobalStar Donor Advised Fund was an administrative error and that the Reporting Person has no pecuniary interest in that fund.
Astera Labs director Stefan A. Dyckerhoff reported insider transactions on 08/13/2025. The filing shows dispositions of common stock: 11,000 shares and 74,154 shares reported as sold. The form lists the reporting person as a director and indicates multiple indirect holdings held through trusts and a limited partnership.
The schedule reports 353,064 shares2,351 shares to be issued upon vesting of restricted stock units and that the reporting person disclaims beneficial ownership except for pecuniary interest.
Astera Labs CFO Michael Truett Tate reported multiple stock sales on 08/12/2025. The Form 4 shows dispositions of 66,561, 32,374 and 1,065 shares of common stock sold at weighted-average prices of approximately $190.8154, $191.9162 and $192.5156, respectively, and an additional 278,373 shares disposed, for a combined total of 378,373 shares sold on that date. Following the reported transactions, the filing lists beneficial ownership totals of 434,935, 402,561 and 401,496 shares in related entries, with indirect ownership noted by the Tate 1997 Living Trust and by GlobalStar DAF. The filing includes weighted price ranges for each sale series and a signature by an attorney-in-fact dated 08/14/2025. The reporting person disclaims beneficial ownership of trust- and DAF-held shares except for any pecuniary interest.
AllianceBernstein L.P. reports beneficial ownership of 6,391,580 shares of Astera Labs Inc common stock, representing 3.9% of the outstanding class. The filing states these shares are held for client discretionary investment advisory accounts and were acquired solely for investment purposes.
The submission provides a voting and dispositive-power breakdown: sole voting power for 6,157,426 shares, sole dispositive power for 6,390,751 shares and shared dispositive power for 829 shares. AllianceBernstein identifies as organized in Delaware and notes it is majority owned by Equitable Holdings, Inc. but operates under independent management; the filer certifies the holdings are in the ordinary course of business and not intended to influence control.
Astera Labs, Inc. (ALAB) filed a Form 144 notifying a proposed sale of 100,000 common shares with an aggregate market value of $19,118,990. The shares are to be sold on NASDAQ around 08/12/2025 through Morgan Stanley Smith Barney LLC. The filing lists 166,219,140 shares outstanding, so the proposed sale equals approximately 0.06% of outstanding shares.
The securities were acquired as founder stock on 09/11/2020. The filing also discloses recent sales by TATE 1997 LIVING TRUST: three tranches on 08/07/2025 totaling 100,000 shares for combined gross proceeds of $17,138,480.00, and a 05/30/2025 sale of 500,000 shares for $45,098,194.00. The filer attests they do not know any undisclosed material adverse information.
Astera Labs director Stefan A. Dyckerhoff reported multiple sales of company common stock on 08/07/2025 and 08/08/2025 totaling 52,000 shares. The filings show weighted-average sale prices in ranges reported between $172.50 and $175.86. Following the reported transactions one line reports direct beneficial ownership of 74,154 shares and the filing discloses substantial indirect holdings, including 364,064 shares held by a trust and several ~3,765-share holdings by named entities. The form notes 2,351 shares to be issued upon vesting of restricted stock units and includes standard disclaimers that certain partnership and trust holdings are disclaimed except for pecuniary interest. The Form 4 is signed and dated 08/11/2025.
Mohan Jitendra, Chief Executive Officer and director of Astera Labs (ALAB), reported sales of company common stock on 08/07/2025 executed under a Rule 10b5-1 trading plan adopted December 2, 2024. The Form 4 discloses a weighted average sale price of $170.3278 and lists lot-level price ranges and quantities for the transactions in a detailed footnote.
The filing also discloses amounts held indirectly by trusts: a Living Trust with 4,280,002 shares; a Trust with 699,999 shares; 2021 Trusts 1 and 2 with 700,000 shares each; and 2022 Trusts 1 and 2 with 450,001 shares each. The reporting person disclaims beneficial ownership of those trust holdings except to the extent of any pecuniary interest.
Michael Truett Tate, Chief Financial Officer of Astera Labs, reported multiple transactions in the issuer's common stock on August 7–8, 2025. The filing discloses a total of 278,373 shares sold across several block transactions with reported weighted-average prices of $169.608, $170.3396, $171.4778 and $173.8234, and price ranges noted between $169.05 and $174.04. The report also records bona fide gifts of 7,500 shares to the GlobalStar DAF and 10,000 shares to a non-affiliated person.
The filing shows indirect ownership through the Tate 1997 Living Trust and GlobalStar DAF and disclaims direct beneficial ownership beyond any pecuniary interest. Following the reported transactions, the Tate Trust's reported indirect holdings are shown as 501,496 shares. Footnotes state the seller will provide details on the number of shares sold at each separate price upon request.
Gajendra Sanjay, President and COO of Astera Labs (ALAB), reported automated sales under a Rule 10b5-1 plan adopted November 30, 2024. On 08/07/2025 he sold a total of 280,000 shares in multiple transactions at prices ranging approximately from $165.17 to $175.00. Following the sales, the filing shows Trust 1 holds 5,525,545 shares, Trust 2 and Trust 3 each hold 695,000 shares, and the reporting person directly holds 2,262,318 shares. The filing disclaims beneficial ownership of the trust-held shares except for any pecuniary interest, and the reporting person offers to provide transaction-level price details on request.
Astera Labs' Form 144 discloses a proposed sale of 26,000 common shares on NASDAQ through broker Stifel, with an aggregate market value of $4,556,737.00 and the issuer reported 162,150,000 shares outstanding. The filing shows the shares were acquired in private placements: 1,000 on 05/17/2022 and 25,000 on 11/08/2019. A related sale by Stefan A Dyckerhoff of 26,000 shares on 08/07/2025 for $4,508,959.00 is also listed. The notice includes the seller's representation that they do not possess undisclosed material adverse information and contains the standard legal warning about intentional misstatements.